Tübingen/ Hamburg — German health­care specia­list SHS Capi­tal is selling its stake in Spie­gel­berg to Luciole Medi­cal AG. Spie­gel­berg, a medi­cal tech­no­logy company based in Hamburg, Germany, deve­lops, produ­ces and distri­bu­tes highly specia­li­zed cathe­ters and measu­ring probes for neuro­sur­gi­cal appli­ca­ti­ons in the brain and has been able to grow stron­gly in recent years. Luciole Medi­cal AG, which specia­li­zes in cere­bral moni­to­ring and measu­re­ment of oxygen satu­ra­tion in the brain, expands its product range with the acqui­si­tion of Spiegelberg

Foun­ded in 1986, Spie­gel­berg has become a reco­gni­zed provi­der in the field of intra­cra­nial pres­sure measu­re­ment. Signi­fi­cant growth was gene­ra­ted during the holding period of SHS. Today, the company is one of the leading manu­fac­tu­r­ers of ICP probes for intra­cra­nial pres­sure measu­re­ment as well as the produc­tion of high-quality cathe­ters for ventri­cu­lar drai­nage, subdu­ral drai­nage or lumbar drai­nage and matching exter­nal ventri­cu­lar drai­nage (EVD) sets. The company works with reco­gni­zed rese­arch insti­tu­tes as well as leading clinics and specia­lists in neuro­sur­gery to deve­lop products that are best tail­o­red to the patient.

With Luciole Medi­cal AG, the company now has the oppor­tu­nity to leverage stra­te­gic syner­gies, both in product deve­lo­p­ment and sales. The company’s products comple­ment each other ideally, and the sales chan­nels and target custo­mers with neuro­cli­nics, hospi­tals and specialty distri­bu­tors are almost iden­ti­cal. Toge­ther, the compa­nies have the oppor­tu­nity to indi­vi­dua­lize and opti­mize compre­hen­sive brain func­tion monitoring.

“We are deligh­ted to have found a part­ner in Luciole Medi­cal AG that will enable us to offer further inno­va­tive products on the market and thus achieve an even better market posi­tion,” said Spie­gel­berg CEO Stefan Paschko.

“Spie­gel­berg can be descri­bed as the perfect addi­tion to our product port­fo­lio. The signi­fi­cant growth of the company, the profi­ta­ble core busi­ness, but also the strong inter­na­tio­nal presence of the company convin­ced us. We are looking forward to the upco­ming coope­ra­tion and the nume­rous oppor­tu­ni­ties we will exploit toge­ther,” explains Luciole CEO Phil­ippe Dro.

“We are plea­sed to now trans­fer our shares in Spie­gel­berg to a suita­ble part­ner after seve­ral successful years of colla­bo­ra­tion. This merger is the ideal synergy of two inno­va­tive compa­nies that will enhance both market presence and treat­ment opti­ons in the field of cere­bral health of the brain,” says SHS Mana­ging Direc­tor Uwe Stein­ba­cher.

About Spie­gel­berg

The medi­cal tech­no­logy company Spie­gel­berg GmbH & Co KG, based in Hamburg, was foun­ded in 1986 by Dr. Andreas Spie­gel­berg. Spie­gel­berg deve­lops, manu­fac­tures and markets products for intra­cra­nial pres­sure measu­re­ment, cere­bro­s­pi­nal fluid drai­nage and IAP measu­re­ment in more than sixty count­ries. The focus here is on relia­bi­lity, robust­ness and ease of use, so that work is made easier and the patient’s treat­ment takes center stage. www.spiegelberg.de

About SHS Gesell­schaft für Betei­li­gungs­ma­nage­ment mbH

SHS, an indus­try inves­tor, is a private equity firm foun­ded in 1993 that makes invest­ments in health­care compa­nies in Europe. The focus of invest­ments is on expan­sion finan­cing, share­hol­der chan­ges and succes­sion situa­tions. “Buil­ding Euro­pean Health­care Cham­pi­ons” is the invest­ment philo­so­phy accor­ding to which SHS finan­ces and deve­lops port­fo­lio compa­nies. The Tübin­­gen-based inves­tor is taking both mino­rity and majo­rity stakes. SHS funds’ natio­nal and inter­na­tio­nal inves­tors include pension funds, funds of funds, foun­da­ti­ons, family offices, stra­te­gic inves­tors, entre­pre­neurs and the SHS manage­ment team. The equity or equity-like invest­ment of the AIF is up to €40 million. Volu­mes beyond this can be imple­men­ted with a network of co-inves­­tors. In its invest­ment decis­i­ons, SHS places strong empha­sis on the conside­ra­tion of ESG aspects and has ther­e­fore commit­ted itself to the guide­lines of the UN PRI. SHS is curr­ently inves­t­ing from its sixth fund, which was laun­ched in 2022 and has a volume of appro­xi­m­ately € 250m.
www.shs-capital.eu

About Luciola Medical

Luciole Medi­cal AG was foun­ded in Zurich, Switz­er­land and has rese­ar­ched and deve­lo­ped a deep under­stan­ding of brain hemo­dy­na­mics to the field of brain moni­to­ring. The company is led by an expe­ri­en­ced manage­ment team and board of expe­ri­en­ced medi­cal tech­no­logy execu­ti­ves and entre­pre­neurs. www.luciolemedical.com